Pulmonary Exacerbations in Cystic Fibrosis

Pediatric Pulmonology

Volumn 37, Issue 5, 2004, Pages 400-406

  Rabin, Harvey R ^a,h   Butler, Steven M ^b   Wohl, Mary Ellen B ^c   Geller, David E ^d   Colin, Andrew A ^c   Schidlow, Daniel V ^e   Johnson, Charles A ^b   Konstan, Michael W ^f   Regelmann, Warren E ^g  

^a UNIVERSITY OF CALGARY   (Canada)

^b GENENTECH INC   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NEMOURS CHILDREN S HOSPITAL   (United States)

^e ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^h Departments of Medicine and Community Health Sciences   (Canada)

Author keywords

Clinical trials; Cystic fibrosis; Epidemlologic studies; Pulmonary exacerbations

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ASTHMA; CHILD; COUGHING; CYSTIC FIBROSIS; DATA BASE; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUSITIS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LOGISTIC MODELS; LUNG DISEASES; MALE; MULTICENTER STUDIES; ODDS RATIO;

EID: 2442480846     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20023     Document Type: Article

References (16)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-1256.
2. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
3. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
4. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23-30.
5. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation Consensus Conference. J Pediatr 1994;124:177-192.
6. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
7. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001; 31:436-442.
8. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, Schidlow DV, Stokes DC, Wohl ME, Kaplowitz H, Wyatt MM, Stryker S. Epidemiologic study of cystic fibrosis: design and implementation of a prospective multicenter, observational study of patients with cystic fibrosis in the US and Canada. Pediatr Pulmonol 1999;28:231-241.
9. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
10. Hamill PV, Drizd TA, Johnson CI, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 1979;32:607-629.
11. SAS Institute, Inc. SAS/STAT user's guide. Version 6. 4th ed. Cary, NC: SAS Institute, Inc.; 1994.
12. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-188.
13. Cystic Fibrosis Foundation. Consensus Conference: Microbiology and infections diseases in cystic fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1994. p 1-26.
14. Fiel SB. Clinical management of pulmonary disease in cystic fibrosis. Lancet 1993;341:1070-1074.
15. Schidlow DV, Taussig LM, Knowles MR. Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1993;15:187-198.
16. Nickerson BG, Lemen RJ, Gerdes CB, Wegmann MJ, Robertson G. Within-subject variability and percent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 1980;122:859-866.